Surgery Partners, Inc. (SGRY)
Valor JustoFundamental
53
Precio
$13.64
Capitalización Bursátil
$1.82B
Parte 1 · Cuánto vale la empresa
Resumen
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$3.37B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-89M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$196M
Patrimonio Neto Total
$1.71B
Pasivo Total
$4.99B
Ratio de Liquidez
1.95
Cobertura de Intereses
-
Deuda/EBITDA
7.18
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$17.03
Precio Actual
$13.64
Margen de Seguridad
+19.9%
Rango de Valor Justo
$14.57 - $19.50
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-4.5%
Ratio P/B
1.09
P/FCF
9.68
Margen Bruto
-
ROIC
4.1%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
4.1%
WACC
4.9%
ROIC − WACC
-0.8 pp
El ROIC está en línea con el coste del capital: la empresa apenas cubre su coste de capital.
Criterios de Análisis Fundamental
Superado (12)
- P/FCF 9.68
- P/B Ratio 1.09
- Debt/Equity ratio
- Operating Margin 11.4%
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 12.2%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 14.8%
- Share Dilution 1.0%
- Net Margin Trend -2.6% vs -5.6%
- Piotroski F-Score 5/9
Fallido (9)
- EPS shows upward trend
- Price CAGR -0.85%
- ROIC 4.1%
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- ROE -5.3%
No disponible (6)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
El número de acciones es estable
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. J. Eric Evans | CEO & Director | 48 |
| Mr. David T. Doherty CPA | Executive VP & CFO | 53 |
| Ms. Jennifer B. Baldock J.D. | Executive VP and Chief Administrative & Development Officer | 54 |
| Ms. Marissa A. Brittenham | Executive VP & Chief Strategy Officer | 40 |
| Mr. W. Trent Webb | Division President South | 45 |
| Mr. Justin R. Oppenheimer | Executive VP & COO | 40 |
| Mr. Jon Fredrickson | Senior VP & Chief Information Officer | - |
| Ms. Roxanne Womack | Senior VP & Chief Compliance Officer | - |
| Mr. Spencer Clark | General Counsel & Senior VP | - |
| Ms. Danielle Burkhalter | Executive VP & Chief Human Resources Officer | 40 |
Riesgo de Auditoría
9
Riesgo del Consejo
6
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-03-02
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-10
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-17
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for SGRY, sourced from Markets Gazette.
- 3/3/2026NEGATIVESurgery Partners Stock Hits 52-Week Low - Here's Why
Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.
- 2/23/2026NEGATIVESurgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million
Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.
via Markets Gazette